Lipoprotein lipase and hepatic triacylglycerol lipase activities in peripheral and skeletal muscle lymph.
We studied the interstitial fluid concentration of two lipid-metabolizing enzymes (lipoprotein lipase and hepatic triacylglycerol lipase) to determine their importance in interstitial modification of filtered lipoproteins. Despite the use of a very sensitive lipase assay (1 nmol of fatty acid release/ml/hr), lipase activities in plasma and in peripheral and skeletal muscle lymph from control dogs were below the sensitivity of our assay. After heparin injection, hepatic triacylglycerol lipase and lipoprotein lipase activities in plasma were similar. However, the postheparin hepatic triacylglycerol lipase activities in peripheral and skeletal muscle lymph were only 1.4% and 1.1%, respectively, those of plasma. This concentration is considerably less than the lymph concentration of albumin, which has a similar size to the lipases but has a lymph concentration of 30% to 40% of plasma. Lipoprotein lipase activity in peripheral lymph and skeletal muscle lymph was 2.7% and 4.8%, respectively, of plasma activity. Since lipoprotein lipase has a similar size as hepatic triacylglycerol lipase, the disproportionate amount of lipoprotein lipase in lymph as compared to hepatic triacylglycerol lipase could be due to heparin crossing the capillary endothelium and displacing lipoprotein lipase from peripheral cells. Injection of radioactive heparin confirmed that it does cross into the interstitial space in sufficient concentrations to displace lipase from peripheral cells. We conclude that most of the lipase found in lymph after heparin injection is derived from peripheral cells and not from plasma. Furthermore, hepatic triacylglycerol lipase does not play a role in high density lipoprotein remodeling in interstitial fluid. Therefore, it seems likely that the considerable remodeling of high density lipoprotein that we found previously results from its interaction with peripheral cells.
Department of Physiology, Louisiana State University Medical Center, New Orleans.
J
J
Huang
C H
CH
Sloop
P S
PS
Roheim
L
L
Wong
D000818:Animals; D004285:Dogs / Q000097:blood; D006493:Heparin / Q000097:blood / Q000378:metabolism / Q000494:pharmacology; D007275:Injections, Intravenous; D008049:Lipase / Q000032:analysis / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D008066:Lipolysis / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000097:blood / Q000378:metabolism*; D008099:Liver / Q000201:enzymology*; D008196:Lymph / Q000201:enzymology*; D008892:Milk / Q000032:analysis; D009132:Muscles / Q000378:metabolism*; D009994:Osmolar Concentration
D006493:Heparin; D008049:Lipase; D008071:Lipoprotein Lipase